Literature DB >> 2458490

Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene.

J A Zaia1, J J Rossi, G J Murakawa, P A Spallone, D A Stephens, B E Kaplan, R Eritja, R B Wallace, E M Cantin.   

Abstract

Antiviral effects were characterized for two oligodeoxyribonucleoside methylphosphonates synthesized in an antisense (3'-TCTTAACC-5') or a sense (5'-AGAATTGG-3') orientation, based on the RNA sequence of the first splice acceptor site of the tat-3 gene of human immunodeficiency virus (HIV) (5'...AGAAUUGG...3'). The development of syncytial cells and supernatant reverse transcriptase was inhibited by a single exposure to the antisense HIV, and HIV RNA synthesis was inhibited by both antisense and sense methylphosphonates but not by a control herpes simplex virus antisense sequence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458490      PMCID: PMC253546     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

Review 1.  The role of antisense RNA in gene regulation.

Authors:  P J Green; O Pines; M Inouye
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

2.  Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation.

Authors:  B M Paterson; B E Roberts; E L Kuff
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

3.  Preparation of oligodeoxyribonucleoside methylphosphonates on a polystyrene support.

Authors:  P S Miller; C H Agris; A Murakami; P M Reddy; S A Spitz; P O Ts'o
Journal:  Nucleic Acids Res       Date:  1983-09-24       Impact factor: 16.971

4.  Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis.

Authors:  J G Izant; H Weintraub
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.

Authors:  M L Stephenson; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

7.  Solid-phase syntheses of oligodeoxyribonucleoside methylphosphonates.

Authors:  P S Miller; M P Reddy; A Murakami; K R Blake; S B Lin; C H Agris
Journal:  Biochemistry       Date:  1986-09-09       Impact factor: 3.162

8.  HTLV-III in the semen and blood of a healthy homosexual man.

Authors:  D D Ho; R T Schooley; T R Rota; J C Kaplan; T Flynn; S Z Salahuddin; M A Gonda; M S Hirsch
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  21 in total

1.  Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.

Authors:  M Kulka; C C Smith; L Aurelian; R Fishelevich; K Meade; P Miller; P O Ts'o
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

2.  Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication.

Authors:  J P Leonetti; P Machy; G Degols; B Lebleu; L Leserman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds.

Authors:  P J Furdon; Z Dominski; R Kole
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

Review 4.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

5.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

6.  Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

Authors:  G Li; J Lisziewicz; D Sun; G Zon; S Daefler; F Wong-Staal; R C Gallo; M E Klotman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices.

Authors:  R A Stull; L A Taylor; F C Szoka
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

9.  Sequence dependent effects in methylphosphonate deoxyribonucleotide double and triple helical complexes.

Authors:  L Kibler-Herzog; B Kell; G Zon; K Shinozuka; S Mizan; W D Wilson
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

10.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.